Buprenorphine Hcl Tablet
Product Images NDC 31722-871

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Buprenorphine Hcl (NDC 31722-871). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2 mg 30s Count (01 30)

Label for Buprenorphine Sublingual Tablets 2 mg by Camber Pharmaceuticals, Inc. The label includes dosage strength, NDC number 31722-870-30, barcode, storage instructions, dispensing information, and manufacturer details. The package contains 30 tablets with Rx only status.*

FDA Label Image

8 mg 30s Count (02 30)

Label for Buprenorphine Sublingual Tablets 8 mg from Camber Pharmaceuticals, Inc. The label shows the NDC 31722-871-30 and indicates a package size of 30 tablets. It includes storage instructions, a pharmacist dispensing note, and manufacturer information. The label states "NO VARNISH" vertically on the left.*

FDA Label Image

Mg1 (1)

A text panel listing symptoms, including feeling faint, dizzy, confused, sleepy or uncoordinated, blurred vision, slurred speech, slower than normal breathing, and difficulty thinking clearly.*

FDA Label Image

17 (17)

Text discussing patient access to naloxone for emergency treatment of opioid overdose, emphasizing the importance of having naloxone available for patients at risk, educating on recognizing overdose signs, and advising on naloxone administration and communication with caregivers and family.*

FDA Label Image

Mg2 (2)

A drug facts or safety information text panel listing various medical conditions such as tooth problems, trouble breathing, spine curvature affecting breathing, Addison's disease, enlarged prostate, urination problems, liver, kidney, or gallbladder problems, alcoholism, head injury or brain problems, mental health issues, and adrenal or thyroid gland problems.*

FDA Label Image

Mg3 (3)

This text panel contains a list of possible side effects related to Buprenorphine HCl, including symptoms such as jaundice, loss of appetite, changes in urine and stool color, abdominal pain, and nausea.*

FDA Label Image

Mg4 (4)

This image shows part of a text panel listing side effects or symptoms, including shaking, sweating more than normal, feeling hot or cold more than normal, runny nose, watery eyes, goose bumps, diarrhea, vomiting, and muscle aches. The text appears to be from a drug safety or side effects section.*

FDA Label Image

Mg5 (5)

Text listing side effects associated with the drug includes headache, nausea, vomiting, constipation, pain, increased sweating, and decreased sleep (insomnia). The panel provides information relevant to Buprenorphine HCl tablets.*

FDA Label Image

Chem-fig (Bup HCl Chem Fig)

Chemical structure diagram of Buprenorphine HCl, showing its complex molecular framework with multiple rings, hydroxyl groups, and substituent chains, corresponding to the active ingredient in Buprenorphine HCl tablets.*

FDA Label Image

Ifu-image (Ifu Image)

An instructional illustration showing the process of placing a sublingual tablet under the tongue. The image depicts a person holding a small tablet between their fingers and positioning it beneath the tongue for administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.